About Yu Wang
Castrate-resistant prostate cancer (CRPC) is an aggressive, lethal form of prostate cancer that recurs after initial treatment with androgen deprivation therapy (ADT). ADT targets the androgen receptor (AR), the primary driver of prostate cancer growth and survival.
While CRPC is resistant to current ADT regimens, it is common for tumor cells to continue to rely on AR through various escape mechanisms.
Dr. Yu Wang is developing a novel class of drugs that can target AR-dependent escape mechanisms in CRPC patients.
Synthetic molecules called “peptidomimetic conjugates” that antagonize the AR pathway will be developed and tested in preclinical CPRC models for anti-tumor activity.
What this means for patients: The development of new drugs to treat therapy-resistant prostate cancers is critical. This research may result in the discovery and development of novel drugs to treat patients with tumors that have developed resistance to androgen deprivation therapies but still rely on androgen receptor pathways for growth and survival.
2014 Thomas H. Lee-PCF Young Investigator
Yu Wang, MD, PhD
New York University Lagone Medical Center
Susan Logan, PhD, Michael Garabedian, PhD
Multivalent Peptidomimetic Conjugates in CRPC Treatment